Palbociclib (re-assessment: breast cancer, patient population a1)

Subject:

• Active Substance: Palbociclib
• Name: Ibrance^®
• Therapeutic area: Breast cancer
• Pharmaceutical company: Pfizer Pharma GmbH

Time table:

• Start: 01.07.2022
• Final decision by G-BA: 15.12.2022

Final decision:

• No additional benefit proved